[合成抗甲状腺药物所致粒细胞缺乏症：造血生长因子的疗效]
[Agranulocytosis induced by synthetic antithyroid drugs: efficacy of hematopoietic growth factors].
作者信息
Genet P, Pulik M, Lionnet F, Bremont C
机构信息
Service d'Hématologie, Hôpital Victor Dupouy, Argenteuil.
出版信息
Ann Endocrinol (Paris). 1994;55(1):39-42.
Agranulocytosis is the most serious problem, potentially fatal, that can occur during antithyroid drug therapy. The use of hematopoietic growth factors is an attractive approach to reduce the period of this drug-induced neutropenia. We report two cases of severe antithyroid drug-related agranulocytosis (granulocyte count < 0.1 x 10(9)/L) treated with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). The delay to observe a granulocyte count superior to 1 x 10(9)/L was respectively 1 and 5 days. Our results, with others, clearly show that hematopoietic growth factors are effective in severe antithyroid drug-induced agranulocytosis.
粒细胞缺乏症是抗甲状腺药物治疗期间可能发生的最严重问题，有潜在致命风险。使用造血生长因子是缩短这种药物诱导的中性粒细胞减少期的一种有吸引力的方法。我们报告了两例严重的抗甲状腺药物相关性粒细胞缺乏症（粒细胞计数<0.1×10⁹/L）患者，分别用粒细胞集落刺激因子（G-CSF）或粒细胞-巨噬细胞集落刺激因子（GM-CSF）进行治疗。粒细胞计数升至高于1×10⁹/L的延迟时间分别为1天和5天。我们的结果与其他研究结果清楚地表明，造血生长因子对严重的抗甲状腺药物诱导的粒细胞缺乏症有效。
Zotero 插件